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Abstract: The catechin, epigallocatechin gallate (eGCG), found in green tea, has inhibitory activity 
against a number of protein toxins and was investigated in relation to its impact upon ricin toxin (RT) 
in vitro. The IC50 for RT was 0.08±0.004ng/mL where as the IC50 for RT + 100μM eGCG was 
3.02±0.572ng/mL, indicating that eGCG mediated a significant (p<0.0001) reduction in ricin toxicity. 
This experiment was repeated in the human macrophage cell line THP-1 and IC50 values were 
obtained for RT (0.54±0.024ng/mL) and RT + 100μM eGCG (0.68±0.235ng/mL) again using 100µM 
eGCG and was significant (p=0.0013). The documented reduction in ricin toxicity mediated by eGCG 
was found to be eGCG concentration dependent, with 80 and 100µg/mL (i.e. 178 and 223µM 
respectively) of eGCG mediating a significant (p=0.0472 and 0.0232) reduction in ricin toxicity at 20 
and 4ng/ml of RT in Vero and THP-1 cells (respectively). When viability was measured in THP-1 
cells by propidium iodide exclusion (as opposed to the MTT assays used previously) 10ng/mL and 
5ng/mL of RT was used. The addition of 1000μM and 100μM eGCG mediated a significant (p=0.0015 
and <0.0001 respectively) reduction in ricin toxicity relative to an identical concentration of ricin with 
1μg eGCG. Further, eGCG (100μM) was found to reduce the binding of RT B chain to lactose-
conjugated Sepharose as well as significantly (p=0.0039) reduce the uptake of RT B chain in Vero 
cells. This data suggests that eGCG may provide a starting point to refine biocompatible substances 
that can reduce the lethality of ricin. 
 
Keywords: ricin toxin, endocytosis, polyphenol, epigallocatechin gallate, eGCG, tea        
Abbreviations: Bicinchoninic acid (BCA), bovine serum albumin (BSA), circular	dichroism	(CD) 
commercially acquired RTAC (cRTAC), commercially acquired RTBC (cRTBC), dimethyl sulfoxide 
(DMSO), endoplasmic reticulum (ER), epigallocatechin gallate (eGCG), fetal calf serum (FCS), 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 1-ethyl-3-(3-dimethylamino- 
propyl) phorbol 12-myristate-13-acetate (PMA), recombinant RTBC (rRTBC), ricin toxin (RT), RT B 
chain (RTBC), RT A chain (RTAC), standard error of the mean (SEM). 
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Introduction: There is a clear and pressing need for improved first-line treatment and prophylaxis to 
combat the ever-increasing threat posed by agents of bioterrorism. Amongst these agents is ricin toxin 
(RT), a protein produced by the castor bean (Ricinus communis). RT is rated by the US Centre for 
Disease Control and Prevention as a level B biothreat [1] and has been used within the last 12 years to 
incite terror, with the intention of causing harm, morbidity and mortality within the human population 
[2]. RT is known to be of interest to organizations such as al-Qaeda, thought to be developing a ricin 
“bomb”	 i.e. wrapping ricin powder round explosive devices as a means of dissemination [3]. The 
availability of RT was underpinned by both the intoxication of Roger Bergendorff in 2008 [4] and the 
discovery of RT containing letters sent to Bill Frist in 2004, who was, at the time the US senate 
majority leader [5]. The tangibility (and consequent potency) of these threats is given greater urgency 
by the fact that RT is relatively easy to produce and weaponize in lethal quantities [2]. There is also no 
cure for intoxication with medical support being palliative [6]. The UK and US government exploited 
these observations during the production of “compound W”	 (RT) prior to the Biological and Toxin 
Weapons Convention of 1972 and the Chemical Weapons Convention of 1973 [7]. 
RT is composed of two protein chains joined via a single disulphide bond. The lectinic RT B chain 
(RTBC) is responsible for the binding of the toxin to the cell membrane. Binding is achieved via an 
interaction between RTBC and a terminal galactose or N-acetyl-galactosamine residues, which are 
then internalized [8]. RTBC has a bi-lobal structure, with each lobe having lectinic activity [9] and 
mediates the translocation of RT A chain (RTAC) to the endoplasmic reticulum (ER) [10]. RTBC is 
internalized via clathrin, caveolin and non-clathrin mediated endocytosis and translocation of the RT 
molecule to the ER is achieved via the Golgi body. From the ER, the catalytic RTAC passes into the 
cytosol to mediate the depurination (and inactivation) of ribosomes [10&11]. Critical to RT activity is 
the ability of RTBC to interact with membrane components, as without RTBC, RTAC (and other type 
I ribosome-inactivating protein), is relatively non-toxic [12]. 
Resources have been directed towards developing treatments (aside from prophylactic immunization 
i.e. RiVax) [13], to prevent ricin intoxication post-exposure. To date, several strategies have emerged. 
The first employs a small molecule to inhibit ricin translocation out of the endosome i.e. Retro-2 [14]. 
The second seeks to block ricin uptake or intracellular trafficking via either antibody mediated steric 
hindrance [15&16] or by feeding milk-derived material (i.e. lactose) to exposed individuals [17]. 
RTBC has been documented to have a high lactose binding affinity and lactose is thought to compete 
for cell binding sites on RTBC [17&18]. In addition to the above, the inhibition of a variety of protein 
toxins such as anthrax [19], tetanus [20], botulinum [21] and shiga toxin [22] by polyphenols (found in 
tea), has also been reported. One such polyphenol is epigallocatechin gallate (eGCG) [23]. Here we 
present an evaluation of the inhibitory effect of eGCG upon RT in vitro. An evaluation of potential 
mechanisms of inhibitory activity was also undertaken and has been discussed. 
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Materials and Methods: General chemicals and reagents: TRITON-X-100, propidium iodide, 
glycine, paraformaldehyde, leupeptin hydrochloride, bovine serum albumin (BSA), 1-ethyl-3-(3-
dimethylamino- propyl) phorbol 12-myristate-13-acetate (PMA), the bicinchoninic acid (BCA) assay 
kit, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and anhydrous cell culture 
grade dimethyl sulfoxide (DMSO) were from Sigma-Aldrich (Dorset, UK). The (2R,3R)-2-(3,4,5-
Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate) (eGCG) 
was purchased from Merck (Calbiochem, Nottingham, UK).  
Texas Red-labeled cRTBC: labeling was performed using Texas Red®-X, succinimidyl ester, mixed 
isomers (Invitrogen, Paisley, UK) following the manufacturer’s instructions and as previously 
described for labeling BSA [24]. Commercial (c) RTAC and cRTBC were from Vector labs 
(Peterborough, UK) and re-folded ricin was generated using a previously published protocol [25]. Re-
folded ricin holotoxin was characterized by Western immunoblotting against a known quantity of 
cRTAC and (separately) cRTBC. Where re-folded RT has been documented in the experimental 
section the amounts indicated refer to the amount of RTAC in the preparation and not the total mass of 
protein. This is to control for small inter-batch variability in RTBC content required for RT refolding 
[25]. Antibodies: Monoclonal anti-TGN46 was from AbD Serotech (Kidlington, UK) and the 
polyclonal rabbit anti-RTAC and anti-RTBC were from AbCam, (Cambridge, UK). The anti-mouse 
and anti-rabbit secondary antibodies conjugated with Texas Red- or Alexafluor-488 were from 
Invitrogen (Paisley UK). Horseradish peroxidase-conjugated anti-rabbit and anti-mouse secondary 
antibodies for immunoblotting were from GE Healthcare (Little Chalfont, Bucks, UK).  
Cell culture and Microscopy: RPMI 1640 medium, Dulbecco's minimal essential medium, glutamax, 
penicillin/streptomycin, Dulbecco's Modified Eagles Medium without sodium pyruvate with 
450mg/mL glucose, kanamycin and fetal calf serum (FCS) were from Invitrogen (Paisley, UK). The 6 
well treated cluster plates and sterile 22×22x0.1mm coverslips were from Fisher Scientific 
(Loughborough, UK). Vero cells (ATCC number CCL-81), and THP-1 cells (ATCC number TIB-
202), were from the American Type Culture Collection (ATCC) (Teddington, UK).  
Methods: Cloning and expression of recombinant (r)RTBC: A pUC19-derived plasmid encoding 
E.coli codon optimized RTBC was supplied by Biobasic Inc (Markham, Ontario Ca) and was created 
using published sequences [26] RTBC was amplified from the aforementioned template using the 
following primers: (forward)  ((5’-CAC CGC TGA TGT TTG TAT GGA TCC T and (reverse) 5’- 
TCA AAA TAA TGG TAA CCA TAT TTG). The resulting PCR product was ligated into pET151/D 
Topo (Invitrogen, Paisley, UK) following the manufacturer’s instructions. PCR was performed using 
an Accuzyme PCR kit (Bioline Reagents Limited, London, UK). Sub-cloning was verified by DNA 
sequencing, performed by DNA Sequencing and Services at Dundee University, (Dundee, UK). 
Protein expression, enrichment from bacterial lysate and characterization by immunoblotting was 
performed as previously reported [27].  
Cell culture: Immunofluorescent Microscopy: This methodology has been extensively described and 
discussed previously [24]. Briefly, after being exposed to either Texas Red-labeled RTBC (50μg/mL 
each treatment) or Texas Red-labeled RTBC with eGCG (100µM each treatment), and left for 4h 
under standard incubation conditions, the cells were fixed with 2% (w/v) formalin in PBS at room 
temperature for 20 min, prior to being quenched with 5% (w/v) glycine in PBS containing 0.05% 
(w/v) Triton-x-100 which also served to permeabilized the cells. Following a blocking step using 1% 
(v/v) FBS in PBS, the cells were exposed to an anti-TGN46 primary antibody, (60 min at room 
temperature) and an Alexa488-labelled secondary antibody. Following a subsequent wash step (3 x 
using PBS) the cells were mounted in 50% (w/v) glycerol in PBS containing 1% (w/v) n-propyl 
gallate. Microscopy was performed using an Eclipse 90i microscope (Nikon UK Ltd, Kingston Upon 
Thames, Surrey, UK) fitted with an Apo x60 objective and a DS-Qi1Mc camera. Image acquisition 
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was performed using Advanced Research Elements software version 3.2 (Nikon UK Ltd, Kingston 
Upon Thames, Surrey, UK).  
In vitro toxicity assay: This methodology has been described extensively [28] and assays were 
conducted over 48 or 72h (as stated) with the stated number of replicates [24&25]	Statistical analysis 
was performed using the Prism 6.0b software package (GraphPad Inc. La Jolla, CA, USA) and t-tests 
were unpaired, two tailed. Where concentrations of eGCG above 10μM were used, care was taken to 
remove the eGCG from the culture and to wash the culture 3 times with PBS prior to adding MTT. 
This was necessary to minimize any false positive data resulting from an eGCG interaction with MTT 
(data not shown). Where eGCG was co-administered with RT the two substances were dissolved in 
complete media and left for 60 min at room temperature to come to equilibrium prior to being added 
to cells. Flow cytometer data was acquired using an Accuri C6 flow cytometer (BD Bioscience, 
Oxford UK). THP-1 cells were incubated with RT and eGCG in PBS at the reported concentrations 
and left for the specified time prior to being re-suspended in sterile PBS containing 10ng/mL 
propidium iodide. The cells were then subject to analysis at 488nm. The IC50 values for refolded RT 
are also representative of an extended data set beyond the number of replicates stated as each batch of 
refolded ricin was characterized (in part) by examining its toxicity. 
RTBC uptake experiments: Here 5x10
5
 Vero cells were used to seed individual wells in a 6 well plate. 
The cells were then left overnight in complete media under standard incubation conditions (37
o
C in a 
humidified atmosphere containing 5%(v/v) CO2). The next day, either RTBC (50μg/mL) or RTBC 
plus eGCG (1mM) were added along with a third treatment which had only RTBC added and was kept 
at 0
o
C through out the experiment. The remaining two plates were placed back under standard culture 
conditions. After 4h the cells were washed with ice-cold PBS 3 times and blotted dry, taking care not 
to disturb the monolayer. The monolayers were then dissolved in Laemmli SDS page buffer 
containing 10% (v/v) 2-mercaptoethanol and run on a 12% (w/v) SDS PAGE gel prior to Western 
blotting using standard conditions. After transfer had completed the blots were blocked with PBS 
containing 0.01% (v/v) TWEEN 20 and 5% (w/v) none fat dried milk. Blots were then cut in half to 
allow then to be separately probed with antibodies specific for EEA1 (BD Bioscience; Oxford, UK) 
and RTBC (AbCam, Cambridge, UK) using HRP-conjugated secondary antibodies (GE Healthcare; 
Bucks, UK) following standard protocols and following the manufacturers instructions, using Pierce
TM
 
ECL reagent (Thermo Scientific; Waltham, MA USA). 
In vitro RTBC binding assay: Lactose-conjugated Sepharose (Sigma Chemical Company, Dorset UK) 
was washed 3 times in PBS and either recombinant RTBC commercial RTBC (Vector Labs; 
Peterborough, UK) or commercial RTBC and eGCG was added. This was washed with 10 column 
volumes of PBS. To the beads, 100μl of Laemmli SDS page buffer containing 10% BME) was added 
and this was compared to an equivalent amount of input protein. Following the sedimentation of the 
beads at 12 000 x G at room temperature for 2 min, the supernatant was analyzed by SDS PAGE and 
Western blotting. Detection was performed using an anti RTBC polyclonal antibody (AbCam; 
Cambridge, UK) and an anti-rabbit, HRP-conjugated secondary (Invitrogen, Paisley, UK) using 
Pierce
TM
 ECL reagent (Thermo Scientific; Waltham, MA USA). 
Assessment	 of	 protein	 conformation	 using	 Circular	 Dichroism	 (CD)	 Spectroscopy.	 Proteins	
(0.3mg/ml	in	PBS)	were	analyzed	using	a	Chirascan™	CD	spectrometer,	(Applied	Photophysics,	
Surrey,	 UK),	 and	 data	 was	 acquired	 between	 190-260nm,	 (2	 seconds	 per	 time	 point,	 1nm	
bandwidth)	 at	 20oC.	 Three	 repeats	 were	 taken	 and	 6M	 guanidine	 hydrochloride	 denatured	
samples	were	used	as	a	control.	A	0.1	mm	path-length	was	used.	
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Results: The characterization of RT, RTBC and RTAC was performed (figure 1; panel a) and with the 
exception of the re-folded RT preparation, there was no detectable RTBC in the RTAC preparations 
and no detectable RTAC in the RTBC preparations (figure 1; panel a). These data (figure 1; panel a) 
were important for the validation of the re-folded RT. When re-folded RT was characterized by 
immunoblotting, typically a 2:1 ratio of RTBC to RTAC was obtained (data not shown). This was an 
unavoidable consequence of the protocol that was necessary to ensure that the majority of the RT 
preparation was heterodimeric [25]. Whilst this procedure was not optimal, it was necessary, given the 
current availability of commercial RT holotoxin in the UK. 
 
Figure 1: Characterization of RT and RT components. Panel (a) depicts the immunological profile of commercially 
obtained (ÒcÓ) RTAC, cRTBC, and refolded RT when probed (individually) with antibodies specific for RTAC or RTBC. 
Panel (b & c) document the in vitro toxicity profiles of refolded ricin holotoxin (black circles joined by a dotted line), cRTAC 
(black squares), cRTBC (black triangles, point up) and recombinant RTBC (black triangles, point down), in both Vero (panel 
b) and THP-1 (panel c) cells after 72h when assessed using the MTT assay (in each instance n=8; ± SEM). Data derived 
from these assays are summarized (table 1) where calculated IC50 values are recorded. 
To characterize refolded RT (and its components) in vitro toxicity, both Vero (African green monkey 
kidney) and THP-1 (human macrophage) cell lines were used. These toxicity data (figure1; panel b & 
c) are summarized (in table 1 & 2) and in each instance the refolded RT holotoxin displayed the 
highest level of toxicity (IC50 Vero 0.08±0.004ng/ml; THP-1 0.54±0.024ng/mL), followed by RTAC 
(IC50 Vero 3.525±1.017µg/mL; THP-1 0.068±0.001µg/mL), cRTBC (IC50 Vero 28.625±2.917µg/mL; 
THP-1 9.750±0.744µg/mL) with recombinant RTBC demonstrating the least toxicity (the IC50 was 
100+µg/mL in Vero and 100+µg/mL in THP-1 cells). Having established base-line toxicities for re-
folded ricin, the effect of a known inhibitor of ricin toxin (lactose) [17] as well as that of the 
polyphenol under investigation (eGCG) was investigated, with lactose serving as a positive control 
rather than a gold standard. However, before these interactions could be characterized, baseline 
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toxicities for each of the potential inhibitors were also measured (figure 2; panel a & b) and the IC50 
values calculated (table 1). Initially RT inhibition was assessed using a static concentration of 
potential inhibitor in relation to a variable concentration of RT (figure 2). These data are shown for 
Vero cells (figure 2; panel c) and THP-1 cells (figure 2; panel d). Figure 2 (panel c) documents a 
statistically significant inhibition of RT by: eGCG (43.8µg/ml (i.e. 100µM)) (p>0.0001), when tested 
in Vero cells. The addition of lactose (3.42µg/ml (i.e. 10µM)) to RT prior to incubation with Vero 
cells resulted in an IC50 value that was greater than 10ng/ml (RTAC equivalent) under similar assay 
conditions to those reported in figure 2 (panel d). A similar concentration of lactose gave rise to an 
IC50 value of >10ng/mL (RTAC equivalent) when measured in THP-1 cells. Similarly figure 2 (panel 
d) documents a statistically significant inhibition of RT by eGCG (p=0.0013) when measured using 
THP-1 cells. 
 
  
 
 
 
 
Table 1: documents	the	IC50	values	characterizing	the	individual	experimental	components	used	herein	with	THP-1	and	
Vero	cells	after	72h	(n=6	!	SEM).	These	data	are	derived	from	figure	1	(panels	b	&	c)	and	figure	2	(panels	a	&	b). 
 
 
 
 
 
Table	2:	documents	IC50	values	 for	RT	in	vitro	with	and	without	the	proposed	inhibitors	after	72h	(n=6	!	SEM).	These	
data	are	derived	from	figure	1	(panels	a	&	b)	and	figure	2	(panels	c	&	d).	
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Figure 2: The effects of potential inhibitors upon RT intoxication. The in vitro toxicity profile of both lactose (white 
square) and eGGC (white triangle) upon Vero cell viability over 72h (panel a; n=6 ± SEM) was documented (panel a). A 
similar characterization was performed using activated THP-1 cells (panel b). The viability of cells exposed to a static 
concentration of either lactose (10µM i.e. 3.42µg/ml) (black triangles) or eGGC (100µM i.e. 43.8µg/ml) (black squares), and 
increasing concentrations of RT was documented in Vero cells using the MTT assay (72h; n=6±SEM) (panel c). A similar 
experiment was performed using activated THP-1 cells (panel d). Data derived from these data sets are summarized (table 2) 
where calculated IC50 values are recorded. 
 
Given that eGCG could mediate a significant reduction of RT toxicity when assayed in both Vero and 
THP-1 cells, at a static concentration of eGCG, the next logical question was to ask if a variable 
concentration of eGCG could exert a dose dependent effect upon the toxicity of a static RT 
concentration (figure 3). As Vero and THP-1 cells displayed varying sensitivity to RT (table 2), Vero 
being approximately 6 times more sensitive to RT than THP-1 cells, it was surprising to note that the 
effect of (eGCG mediated) RT inhibition was more profound within the populations of Vero cells 
(table 2; figure 2; panels c & d). A consequence of this was the choice of static concentrations of RT 
used to generate figure 3. Figure 3 (panel a) shows the effect of a lethal concentration of RT (20ng/ml) 
when incubated with increasing amounts of eGCG upon Vero viability after 48h. Figure 3 (panel a) 
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reports that in every instance, a statistical difference was observed relative to cells only treated with 
RT. Here 100, 80, 60 and 40μg/mL of eGCG demonstrated significant (i.e., p=0.0464, p=0.072, 
p=0.0233, p=0.0337 respectively) increases in cell viability relative to an untreated RT control. Figure 
2 (panel b) shows the effect of eGCG (50-200µg/ml) upon THP-1 cell viability after incubation with 
RT (4ng/ml) at a lower concentration. Again a significant difference in viability is reported at a dose 
of eGCG of 100µg/ml (p=0.0232) and 200µg/ml (p=0.0076) relative to the RT only control (figure 3; 
panel b). In an attempt to further rule out the possibility of false positive data resulting from an 
interaction between MTT and eGCG, a flow cytometer was used to measure propidium iodide 
exclusion (as an indication of cell viability) from non-activated (monocyte) THP-1 cells (figure 3; 
panel c and d). This assay used more eGCG than had been previously assayed (figure 2; panels a-d) 
and shows an increase in cell viability (p=<0.0014) (1000µM eGCG relative to 1µM eGCG) when 
THP-1 cells were treated with 10ng/mL RT (figure 3; panel c). When a reduced concentration of RT 
was used (5ng/mL) (figure 3; panel c), a statistically significant increase in cell viability was recorded 
when a dose of 1000µM eGCG was compared to 1µM of eGCG (p>0.0001). 
 
Figure 3: Effect of varying the concentration of eGCG upon RT lethality. Panel (a) documents the effect of varying 
concentrations of eGCG upon a static concentration (20ng/mL) of RT in Vero cells. Cell viability was documented and 
statistically significant differences in viability were recorded for; 40 (p=0.0464), 60 (p=0.0472), 80 (p=0.0233) and 
100µg/ml (p=0.0337) eGCG relative to no eGCG and 20ng RT. Viability data in response to challenge with 4ng/ml RT and 
varying concentrations of eGCG was also recorded using THP-1 cells (panel b). Statistically significant variation from THP-
1 viability after treatment with RT and no eGCG was observed at 100 (p=0.0232) and 200 (p=0.0076) µg/ml of eGCG. These 
data sets (panel a & b) were acquired over 48h. These data were acquired using the MTT assay. Flow cytometry and 
propidium iodide exclusion was also used to measure (non-activated) THP-1 viability to further control for any interaction 
between MTT and eGCG (panels c & d). Ricin concentrations of (panel c) 10ng/ml and (panel d) 5ng/ml RT were used and 
data were gathered after a 72h exposure to both RT and eGCG. There was a statistically significant difference in cell 
viability between cells treated with 10ng/ml RT i.e. with: 1000µM eGCG (p=0.0014), 100µM eGCG (p=0.0009) and 10µM 
(p=0.0015) and cells treated with 1µM eGCG (panel c). A statistically significant amount of RT inhibition (5ng/ml) was 
mediated by 10 and 100µg/mL eGCG relative to 1µM eGCG (panel d). The p values were: 1000µM eGCG (p=0.0021), 
100µM/ml (p=0.0021) and 10µM eGCG (p>0.0001) relative to 1µM. The flow cytometry assays were performed 4 times 
each and the data represents the mean ± SEM. 
Running title: Epigallocatechin gallate (eGCG) inhibits ricin	
	 10	
 
In an attempt to understand the mechanism(s) driving the observed reductions in RT toxicity, the 
effect of eGCG was examined upon RTBC. The effect of eGCG upon RTBC was documented (figure 
4; panel a) where the ability of cRTBC to bind to lactose-conjugated Sepharose with and without 
eGCG (100µM) relative to rRTBC (the negative control) was investigated. Reduced cRTBC lectinic 
activity in the presence of eGCG (100µM) was recorded. This observation supported the hypothesis 
that the reduction in toxicity associated with RT in the presence of eGCG may be, at least in part, due 
to an interaction between eGCG and the RTBC, which resulted in relaxed RTBC conformation 
(impacting upon RTBC lectinic activity, cell uptake and RTAC intracellular trafficking).  
This hypothesis was tested by monitoring the uptake of RTBC, with and without eGCG by Vero cells 
over 4h (figure 4; panel b). On account of the relatively short timescale used, the dose of eGCG was 
increased and the results expressed relative to a housekeeper (early endosomal antigen (EEA)1), to 
control for any variability in cell number. Figure 4 (panel b) shows that there was a reduction in RTBC 
uptake by Vero cells (p=0.0039) incubated with RTBC and 1mM eGCG relative to cells only 
incubated with RTBC at 37
o
C and at 0
o
C. The 0
o
C control was necessary as it controlled for non-
specific interactions. It was possible that eGCG was inhibiting endocytosis at such a high 
concentration rather than reducing RTBC uptake via eGCG mediated RTBC conformational 
relaxation, however this point remains to be addressed. What was clear was that less RTBC was 
entering the cells at high concentrations of eGCG, which may account for the reduced toxicity 
observed earlier (table 1). Were this hypothesis true, then it might be predicted that treatment with 
eGCG would alter levels of RTBC cellular uptake and Golgi translocation. The results of testing this 
hypothesis were documented (figure 4; panel c). Figure 4 (panel c; micrographs i to iii) were captured 
in the absence of eGCG and show the co-localization of Texas-Red labeled- cRTBC with a primary 
antibody specific for TGN46 (a Golgi marker), which was labeled with a secondary (anti-mouse) 
antibody conjugated to Alexafluor
¨ 
488. In contrast, figure 4 (panels c; micrographs iv-vi) 
documented no detectable co-localization between TGN46 and Texas Red-labeled cRTBC in the 
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presence of eGCG (100µM). These micrographs support the hypothesis that eGCG altered the activity 
of RTBC. Figure 4 (panel d) shows the CD spectrum of eGCG at a concentration of 100µM in PBS. It 
was of note that eGCG displayed a profound spectra particularly in the 200-230 nm band. This CD 
response of eGCG means that it may hide changes within the RTBC spectra, if any are present. This 
negative peak impacts upon the interpretation of the spectra derived from RTBC (panel e) and its 
summative effect suggests that there was a decrease in order, regarding the secondary (and tertiary) 
conformation of RTBC (panel e). This may represent a loss of (α-helical) secondary structure. This 
data was reinforced given the CD spectra of RTBC without eGCG, which remains very similar to 
those previously published [29]. 
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Figure 4: The effect of eGCG upon RTBC activity. Panel (a) depicts the effect of eGCG (100µM) upon RTBCÕs lectinic 
activity in relation to RTBC binding to lactose-conjugated Sepharose. Panel (b) documents the effect of eGCG upon RTBC 
uptake by Vero cells over 4h relative to a 0
o
C control. A statistically significant (p=0.0039) inhibition of RTBC uptake was 
mediated by eGCG (1000µM). Panel (c) documents the effect of 100µM eGCG upon the Golgi localization of Texas Red-
labeled RTBC after a 60 min (RTBC) pulse and a further 60 min chase. Micrographs (i-iii) show typical co-localization 
between Texas-Red labeled RTBC and the trans-Golgi specific antibody TGN46. Micrographs (iv-vi) demonstrate that in the 
presence of 100µM eGCG, there is no detectable co-localization. Micrographs were representative of the majority of the 
population of cells observed. Arrows denote co-localization and the size bar represents approximately 5 microns. Panels (d 
& e) denote the effect of eGCG upon the CD spectra of RTBC. The spectra of eGCG at 100µM in PBS (dotted line) and 
10µM is shown (panel d) as well as that of RTBC (solid line) as well as RTBC +100µM eGCG (dashed line), +10 µM eGCG 
(dotted line) and +5µM eGCG (dotted and dashed line) in PBS (panel e).  
  
Running title: Epigallocatechin gallate (eGCG) inhibits ricin	
	 13	
Discussion: RT toxicity has been assayed using a variety of methodologies, which have utilized many 
different cell lines. This variety and diversity of methodology, whilst underscoring the robust nature of 
these findings, makes direct comparisons between this work and those of others difficult. Previously, 
we evaluated commercial RT (isolated from Ricinus communis) toxicity using B16 cells in vitro [28] 
after 72h using the same experimental parameters as reported here and the results are comparable. The 
IC50 values published for HUT102 cells [30] are also similar to the values presented herein, once 
experimental variables and the sensitivity associated with different cell lines are considered (table 1 & 
2).  
In order to gauge the efficiency of any inhibitory activity exerted by eGCG, a positive control was 
established. The literature suggested the use of lactose [17] as a suitable inhibitor. Above a lactose 
concentration of 3.4µg/mL, some toxicity was documented (figure 2; panels a & b) presumably due to 
osmotic effects or the effects of lactose upon none-enzymatic glycosylation [31]. The IC50 resulting 
from treating THP-1 cells with escalating doses of RT and 10µM lactose were beyond the maximum 
concentration of RT assayed (10ng/mL), limited by the results of the re-folding procedure used to 
anneal the A and B chains. RT inhibition by lactose was also documented in Vero cells and were 
similar to those documented for THP-1 cells. Supplemental figure 1 also shows the inhibitory effect of 
Lactose in a complex mixture (non-fat dried milk (NFDM)), which surprisingly hints at limited lactose 
bioavailability when NFDM is used in this context. 
Treatment of both Vero and THP-1 cells with eGCG resulted in some toxicity above 10µg/ml and this 
was to be expected as eGCG has previously been reported to induce apoptosis [32]
 
(figure 2; panel a & 
b) and may be linked to eCGCs ability to switch from acting as a free radical scavenger to a free 
radical generator as a function of pH [33]. Little inhibition of RT was recorded at an eGCG 
concentration of 10µM in either cell line (data not shown). Consequently a concentration of 100µM 
(43.8µg/ml) was used. At 100µM eGCG, Vero cells display significant (p<0.0001) resistance to RT 
intoxication when IC50 values were compared (table 2). Similarly eGCG also mediated significant 
inhibition to RT intoxication in THP-1 cells (p=0.0013) upon a comparison of IC50 values relative to 
RT treated cells alone (table 2). These data sets were reinforced when the effect of eGCG upon RT 
intoxication was measured using a static concentration of RT and variable concentrations of eGCG 
(figure 3; panels a-d). It is of note that protection from RT intoxication by eGCG was observed in an 
assay that did not require MTT (figure 2; panels c & d) negating the possibility that the previous data 
sets could be subject to false positives as a result of an interaction between eGCG and MTT. It is also 
important to note that during the assays reported herein, the cells were being stressed by both eGCG 
and RT and it is for this reason we conjecture that 100% protection from RT intoxication was not 
documented.  
The reported reduction in RT toxicity in the presence of eGCG required some mechanistic 
explanation. It was hypothesized that the reduction in RT toxicity was due to an alteration in RTBC 
conformation as a result of either a direct or indirect interaction with eGCG. This interaction has not 
been defined herein. However, others have reported the ability of thearubigin fractions to bind to both 
tetanus toxin [20] and botulinum toxin [34]. Given that in the presence of 100µM eGCG, (i) cRTBC 
loses its ability to efficiently bind to lactose conjugated-Sepharose (figure 4; panel a), (ii) that eGCG 
reduces RTBC cellular uptake (figure 4; panel b) either via an interaction with RTBC, an interaction 
with the cell, reducing endocytic internalization or both, and that (iii) after exposure of Vero cells to 
Texas Red-conjugated cRTBC, little Golgi localization was documented, it was possible that an 
interaction between eGCG and cRTBC leads to a change in RTBC conformation which renders it less 
able to bind to sugars (receptors) on the cell membrane. A consequence of impaired RTBC cell 
binding would predict that cellular uptake was dramatically reduced as it is likely that RTBC would 
undergo fluid-phase capture as opposed to a more efficient receptor mediated means of cellular entry 
facilitating Golgi localization. This hypothesis is shown diagrammatically (figure 5). It is of note that 
there was some interaction between eGCG upon RTAC, which may also hint at the possibility of 
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eGCG activity post-RTAC cytosolic translocation i.e. once RTAC has translocated to the cytosol 
(figure 5). However if a synergy between lactose and eGCG is considered, it is unlikely that any effect 
of eGCG upon RTAC would be measurable in vitro. This conjecture is based upon the efficient way 
lactose prevents RTBC cell uptake and Golgi translocation i.e. the RTAC would be prevented from 
reaching the cytosol by virtue of the interaction of both lactose and eGCG with the B chain. This 
observation is further underscored by the published data documenting only 5% of internalized ricin in 
the Golgi apparatus [35]. Whilst both eGCG and lactose inhibited RTBC may well enter the cell 
(inefficiently) by fluid phase endocytic capture, it is unlikely that this cargo could escape 
endolysosomal translocation and destruction. These data / observations do lead to questions about the 
specificity of eGCG with regards to RT A and B chains however it is worth mentioning at this 
juncture that eGCG is not ubiquitously active against all protein toxins as the cytotoxicity of 
Clostridium difficile toxin A is unaffected by 100µg/mL of eGCG (data not shown) in Vero cells after 
72h. 
The CD spectrum of RTBC has been previously published [29] and agrees with the spectra of 
commercial RTBC documented herein (figure 4; panel e). The CD spectra of eGCG (100µM), was 
recorded and surprisingly a negative peak was evident between 200-220nm. This observation helps 
when interpreting the CD spectra of RTBC upon the addition of eGCG (100µM), which may have an 
additive effect. As the 190-210nm region of the CD spectra is sensitive to alterations in the amount of 
helix present, it is likely that upon the addition of eGCG there was a marked change in the amount of 
disorder associated with RTBC i.e. the addition of eGCG results in a decrease in the amount of α-
helix within the RTBC. In addition, there was little significant change (given the presence of a 
contribution to the spectra from eGCG), in the RTBC CD spectra at 232nm, previously reported to be 
due to disulphide bond transition [29]. This may indicate that eGCG was not reducing disulphide 
bonding or the environments of the disulphide bonds between RTBC and RTAC during toxicity 
experiments, which would result in RTAC behaving like a type I RIP. As no large structural 
observations were documented in the spectra of RTAC upon the addition of eGCG (data not shown), it 
is difficult to draw any conclusions about the effects of eGCG upon RTAC structure using this 
methodology. Further, an investigation into the ability of eGCG to inhibit RTAC using an in vitro 
translation assay was also inconclusive. Although all of the components of this assay behaved as the 
literature would suggest, the assay itself was inhibited by eGCG at 100 µM (though not at an eGCG 
concentration of 10µM) (data not shown). This makes attributing specificity between an eGCG and 
RTBC interaction difficult and doesnÕt rule out an inhibition of RTAC by eGCG, contributing to the 
reduced levels of RT toxicity observed in the presence of eGCG (table 2). The reduction in biological 
activity observed was not simply a consequence of protein precipitation and this was reflected not only 
in the CD data, but also visually during the execution of experiments. No clouding of solutions or 
increase in turbidity was observed at any time in response to the addition of eGCG. Given that the CD 
experiments required a protein concentration of 0.3mg/ml, if protein precipitation was occurring it 
would have been easy to detect (as it is when 6-His tagged recombinant proteins all too frequently 
precipitate during dialysis against PBS).  
Tetley have estimated that the level of flavonoids in their classic blend to be approximately 156 
mg/cup and that of these flavonoids eGCG was predominant [36]. This is in contrast to a recent study 
evaluating the total flavonoid content of the green tea (16.3 mg/g ± 0.9 mg/g (±SE; n=38) whilst the 
average for the black teas was lower at 12.9 mg/g ± 0.8 mg/g (±SE; n = 34) [37] Given the eGCG 
activities recorded here, it is unlikely that a cup of tea could provide a feasible antidote to RT 
intoxication. Given that lactose would only be effective prior to the cellular uptake of RT and the 
cytosolic translocation of RTAC, and that there are a significant number of people who are lactose 
intolerant, these intriguing results suggest that there may be value in further investigating eGCGÕs 
ability to reduce RTs toxicity with a view to isolating active groups or moieties within eGCG in order 
to improve its RT inhibitory potential. 
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Figure 5: Cartoon depicting the intracellular trafficking of RT with and without an inhibitor (eGCG or lactose). This 
cartoon proposes a mechanism to explain the inhibition of RT toxicity mediated by eGCG. These data are adapted from: [16, 
35]. 
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